In 2019, Qing Wang founded Complete Omics with early angel VC backing to build the world’s leading deep-proteome measurement platform and unlock a new molecular layer for precision medicine.
Complete Omics Founded to Build the Measurement Infrastructure of the Human Proteome
In 2019, Complete Omics Inc. was founded by Qing Wang with the support of early angel investors who recognized the transformative potential of clinical proteomics in precision medicine. The company was established with a bold mission: to make the human proteome measurable at scale and translate molecular discoveries into deployable clinical technologies.
After more than a decade of research at Johns Hopkins University School of Medicine in the laboratory of Bert Vogelstein, Wang had developed a deep conviction that the next revolution in medicine would come from systematic measurement of proteins across human diseases.
While genomics had revealed the genetic blueprint of cancer and many other diseases, Wang observed that the field still lacked a scalable platform capable of measuring the functional molecular layer of biology — the proteome — directly in clinical samples.
This insight led to the founding of Complete Omics.
From Scientific Discovery to Platform Company
The company was built on a series of scientific advances developed over the preceding decade, including technologies for:
- mutation-specific protein detection
- targeted proteomics biomarker validation
- ultra-sensitive peptide quantification
- neoantigen detection for precision immunotherapy
These innovations demonstrated that proteins and peptides derived from disease-driving genetic alterations could be measured directly using advanced mass spectrometry workflows.
However, Wang believed the true opportunity was far larger than individual assays.
Rather than developing isolated biomarker tests, Complete Omics was founded to build a scalable measurement platform capable of profiling thousands of proteins simultaneously across large clinical cohorts.
Building the Proteomic Layer of Precision Medicine
The founding vision of Complete Omics was rooted in a simple but powerful idea:
Genomics reveals the blueprint of disease, but proteins represent the functional execution layer of biology.
To fully realize precision medicine, healthcare systems would need a reliable way to measure this layer across patients, diseases, and therapeutic interventions.
Complete Omics was therefore designed as a platform company, combining:
- advanced mass spectrometry technologies
- engineered sample preparation workflows
- quantitative peptide libraries
- large-scale clinical cohort analysis
- AI-driven multi-omics data interpretation
Together, these technologies would eventually evolve into the company’s core platforms, including Complete360® and Valid-NEO®, enabling ultra-deep molecular characterization of human disease.
The Beginning of a New Category
The founding of Complete Omics marked the transition from a decade of academic innovation to the creation of a company dedicated to industrializing clinical proteomics.
Supported by early angel investors who shared this long-term vision, the company set out to build the infrastructure required to transform proteomics into a scalable clinical technology.
What began as a small startup focused on advancing targeted proteomics has since grown into a platform-driven biotechnology company working to enable large-scale measurement of the human proteome for disease detection, therapeutic development, and precision medicine.
At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr.